InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder

InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.
Fierce Pharma

After scrapped trial, InflaRx could tap partner to revive development of COVID drug in rare skin disorder

In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
Healio

Pain scores may indicate treatment response in patients with pyoderma gangrenosum

Please provide your email address to receive an email when new articles are posted on . A minimal important difference of 7-day pain scores was a 2-point improvement on an 11-point scale. A 2-point ...
Healio

First patient dosed in phase 3 vilobelimab trial for pyoderma gangrenosum

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ulcerative pyoderma gangrenosum is a rare disease with ...
Business Insider

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
Finanznachrichten

InflaRx N.V.: InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...